July 08, 2020

Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for Surgery

NRG Oncology opened a Phase I trial (NRG-GI007) examining the safety of combining the administration of the viral agent Telomelysin during endoscopy, with chemoradiation for patients with advanced esophageal cancer who are not candidates for surgery.

Read the study